Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc (NQ: LTRN )

3.510 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lantern Pharma Inc

< Previous 1 2 3 4 5 6 Next >
Lantern Pharma to Present New Preclinical Data at Three Upcoming Scientific Conferences
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Present at the ThinkEquity Conference on Wednesday, October 26 at 1:00 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Touts Encouraging Positive Efficacy For Pancreatic Cancer Candidate
Via Benzinga
Recap: Lantern Pharma Q2 Earnings
  Lantern Pharma (NASDAQ:LTRN) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Adamis Pharmaceuticals (NASDAQ:ADMP) shares moved upwards by 28.1% to $0.19 during Wednesday's pre-market session. The market value of their outstanding shares is at $28.1 million. 
Via Benzinga
Lantern Pharma to Present at The MicroCap Rodeo Presents The Windy City Roundup 2022 on Wednesday, October 12 at 11:00 a.m. ET
Via ACCESSWIRE
Lantern Pharma to Present at Upcoming Investor Conferences
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting
From Lantern Pharma Inc.
Via Business Wire
Earnings Scheduled For March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, featuring Peter Houghton, Ph.D.
From Lantern Pharma Inc.
Via Business Wire
Treating Pediatric Cancer? How Lantern Pharma Hopes To Improve The Lives Of Pediatric Cancer Patients During Childhood Cancer Awareness Month
Every September organizations have worked to raise awareness for childhood cancer by participating in childhood cancer awareness month.  
Via Benzinga
Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma CEO & President, Panna Sharma, to Speak at H.C. Wainwright’s 24th Annual Global Investment Conference in September 2022
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Report Second Quarter 2022 Operating & Financial Results on August 8th, 2022 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma's New Phase 2 Clinical Trial –Harmonic™ — Approved for Launch by the FDA
When most people think of lung cancer, they often picture a smoker. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
  
Via Benzinga
Lantern Pharma Gets FDA Clearance for Mid-Stage Lung Cancer Study
The Food and Drug Administration (FDA) has announced clearance to Lantern Pharma (NASDAQ: LTRN) to proceed with Phase 2 clinical trial of its investigational new drug LP-300 in combination with... 
Via Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Management to Speak at Multiple Investor and Scientific Conferences in May 2022
From Lantern Pharma Inc.
Via Business Wire
Recap: Lantern Pharma Q1 Earnings
Lantern Pharma (NASDAQ:LTRN) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Lantern Pharma missed estimated... 
Via Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Lantern Pharma Earnings Preview
Lantern Pharma (NASDAQ:LTRN) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Lantern... 
Via Benzinga
Lantern Pharma Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
ORLANDO, FL / ACCESSWIRE / April 14, 2022 / RedChip Companies, Inc. today announced that Lantern Pharma (NASDAQ:LTRN),a clinical stage biopharmaceutical company using its proprietary RADR® artificial... 
From RedChip
Via AccessWire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Lantern Pharma: Q4 Earnings Insights
Lantern Pharma (NASDAQ:LTRN) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Earnings Outlook For Lantern Pharma
Lantern Pharma (NASDAQ:LTRN) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.